#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=Over the last few decades , accumulating evidence has demonstrated that numerous Interferon ( IFN ) stimulate genes ( ISGs ) can be directly upregulated following virus infection independent of IFN signaling .
1-1	0-4	Over	_	_	_	_
1-2	5-8	the	time[1]	new[1]	_	_
1-3	9-13	last	time[1]	new[1]	_	_
1-4	14-17	few	time[1]	new[1]	_	_
1-5	18-25	decades	time[1]	new[1]	_	_
1-6	26-27	,	_	_	_	_
1-7	28-40	accumulating	abstract[2]	new[2]	_	_
1-8	41-49	evidence	abstract[2]	new[2]	_	_
1-9	50-53	has	_	_	_	_
1-10	54-66	demonstrated	_	_	_	_
1-11	67-71	that	_	_	_	_
1-12	72-80	numerous	abstract[6]	new[6]	appos	1-20[0_6]
1-13	81-91	Interferon	organization|abstract[6]	new|new[6]	coref	17-37
1-14	92-93	(	abstract[5]|abstract[6]	new[5]|new[6]	_	_
1-15	94-97	IFN	abstract|abstract[5]|abstract[6]	new|new[5]|new[6]	coref	1-31
1-16	98-99	)	abstract[5]|abstract[6]	new[5]|new[6]	_	_
1-17	100-109	stimulate	abstract[5]|abstract[6]	new[5]|new[6]	_	_
1-18	110-115	genes	abstract[6]	new[6]	_	_
1-19	116-117	(	_	_	_	_
1-20	118-122	ISGs	abstract	giv	coref	2-4[12_0]
1-21	123-124	)	_	_	_	_
1-22	125-128	can	_	_	_	_
1-23	129-131	be	_	_	_	_
1-24	132-140	directly	_	_	_	_
1-25	141-152	upregulated	_	_	_	_
1-26	153-162	following	_	_	_	_
1-27	163-168	virus	abstract|event[9]	new|new[9]	coref|coref	3-6|8-16[58_9]
1-28	169-178	infection	event[9]	new[9]	_	_
1-29	179-190	independent	_	_	_	_
1-30	191-193	of	_	_	_	_
1-31	194-197	IFN	abstract|abstract[11]	giv|new[11]	coref|coref	2-9[14_11]|19-21[177_0]
1-32	198-207	signaling	abstract[11]	new[11]	_	_
1-33	208-209	.	_	_	_	_

#Text=Indeed , whereas typical ISGs are driven by JAK-STAT signaling , other virally-stimulated genes are upregulated through the IRF3 and NF-κB pathways .
2-1	210-216	Indeed	_	_	_	_
2-2	217-218	,	_	_	_	_
2-3	219-226	whereas	_	_	_	_
2-4	227-234	typical	abstract[12]	giv[12]	coref	2-12[15_12]
2-5	235-239	ISGs	abstract[12]	giv[12]	_	_
2-6	240-243	are	_	_	_	_
2-7	244-250	driven	_	_	_	_
2-8	251-253	by	_	_	_	_
2-9	254-262	JAK-STAT	place|abstract[14]	new|giv[14]	coref	13-22[0_14]
2-10	263-272	signaling	abstract[14]	giv[14]	_	_
2-11	273-274	,	_	_	_	_
2-12	275-280	other	abstract[15]	giv[15]	coref	3-1[19_15]
2-13	281-299	virally-stimulated	abstract[15]	giv[15]	_	_
2-14	300-305	genes	abstract[15]	giv[15]	_	_
2-15	306-309	are	_	_	_	_
2-16	310-321	upregulated	_	_	_	_
2-17	322-329	through	_	_	_	_
2-18	330-333	the	abstract[18]	new[18]	coref	10-26[84_18]
2-19	334-338	IRF3	abstract|abstract[18]	new|new[18]	coref	21-5
2-20	339-342	and	abstract[18]	new[18]	_	_
2-21	343-348	NF-κB	abstract|abstract[18]	new|new[18]	_	_
2-22	349-357	pathways	abstract[18]	new[18]	_	_
2-23	358-359	.	_	_	_	_

#Text=These genes can be called virus stimulated genes ( VSGs ) , and IFNs themselves are VSGs .
3-1	360-365	These	abstract[19]	giv[19]	coref	3-6[21_19]
3-2	366-371	genes	abstract[19]	giv[19]	_	_
3-3	372-375	can	_	_	_	_
3-4	376-378	be	_	_	_	_
3-5	379-385	called	_	_	_	_
3-6	386-391	virus	abstract|abstract[21]	giv|giv[21]	appos|coref	3-10[0_21]|8-16
3-7	392-402	stimulated	abstract[21]	giv[21]	_	_
3-8	403-408	genes	abstract[21]	giv[21]	_	_
3-9	409-410	(	_	_	_	_
3-10	411-415	VSGs	abstract	giv	coref	8-22[60_0]
3-11	416-417	)	_	_	_	_
3-12	418-419	,	_	_	_	_
3-13	420-423	and	_	_	_	_
3-14	424-428	IFNs	abstract[23]	new[23]	ana	3-15[0_23]
3-15	429-439	themselves	abstract[23]|abstract	new[23]|giv	coref	3-17
3-16	440-443	are	_	_	_	_
3-17	444-448	VSGs	abstract	giv	coref	4-3
3-18	449-450	.	_	_	_	_

#Text=Interestingly , VSGs have natural anticancer activities , and they may cause diseases in humans when induced chronically .
4-1	451-464	Interestingly	_	_	_	_
4-2	465-466	,	_	_	_	_
4-3	467-471	VSGs	abstract	giv	coref	6-12
4-4	472-476	have	_	_	_	_
4-5	477-484	natural	abstract[28]	new[28]	ana	4-10[0_28]
4-6	485-495	anticancer	abstract|abstract[28]	new|new[28]	_	_
4-7	496-506	activities	abstract[28]	new[28]	_	_
4-8	507-508	,	_	_	_	_
4-9	509-512	and	_	_	_	_
4-10	513-517	they	abstract	giv	coref	24-18[238_0]
4-11	518-521	may	_	_	_	_
4-12	522-527	cause	_	_	_	_
4-13	528-536	diseases	abstract	new	_	_
4-14	537-539	in	_	_	_	_
4-15	540-546	humans	animal	new	ana	5-3
4-16	547-551	when	_	_	_	_
4-17	552-559	induced	_	_	_	_
4-18	560-571	chronically	_	_	_	_
4-19	572-573	.	_	_	_	_

#Text=To understand their role in host defense and pathogenesis , excellent model systems have been developed .
5-1	574-576	To	_	_	_	_
5-2	577-587	understand	abstract|abstract	new|new	coref|coref|none|none	6-9[41_0]|23-6[225_0]|5-2[0_41]|5-2[0_225]
5-3	588-593	their	animal|abstract[33]	giv|new[33]	coref	8-19[59_33]
5-4	594-598	role	abstract[33]	new[33]	_	_
5-5	599-601	in	abstract[33]	new[33]	_	_
5-6	602-606	host	abstract[33]|person|abstract[35]	new[33]|new|new[35]	coref|coref	6-14|6-14[45_35]
5-7	607-614	defense	abstract[33]|abstract[35]	new[33]|new[35]	_	_
5-8	615-618	and	abstract[33]	new[33]	_	_
5-9	619-631	pathogenesis	abstract[33]|substance	new[33]|new	_	_
5-10	632-633	,	_	_	_	_
5-11	634-643	excellent	abstract[38]	new[38]	_	_
5-12	644-649	model	abstract|abstract[38]	new|new[38]	_	_
5-13	650-657	systems	abstract[38]	new[38]	_	_
5-14	658-662	have	_	_	_	_
5-15	663-667	been	_	_	_	_
5-16	668-677	developed	_	_	_	_
5-17	678-679	.	_	_	_	_

#Text=However , there are still important gaps in our understanding of VSGs and host defense .
6-1	680-687	However	_	_	_	_
6-2	688-689	,	_	_	_	_
6-3	690-695	there	_	_	_	_
6-4	696-699	are	_	_	_	_
6-5	700-705	still	_	_	_	_
6-6	706-715	important	abstract[39]	new[39]	_	_
6-7	716-720	gaps	abstract[39]	new[39]	_	_
6-8	721-723	in	abstract[39]	new[39]	_	_
6-9	724-727	our	abstract[39]|person|abstract[41]	new[39]|acc|new[41]	ana	9-1
6-10	728-741	understanding	abstract[39]|abstract[41]	new[39]|new[41]	_	_
6-11	742-744	of	abstract[39]|abstract[41]	new[39]|new[41]	_	_
6-12	745-749	VSGs	abstract[39]|abstract[41]|abstract|abstract[43]	new[39]|new[41]|giv|giv[43]	coref|coref	6-12[43_0]|7-11[50_43]
6-13	750-753	and	abstract[39]|abstract[41]|abstract[43]	new[39]|new[41]|giv[43]	_	_
6-14	754-758	host	abstract[39]|abstract[41]|abstract[43]|person|abstract[45]	new[39]|new[41]|giv[43]|giv|giv[45]	coref|coref	9-21|10-27[83_45]
6-15	759-766	defense	abstract[39]|abstract[41]|abstract[43]|abstract[45]	new[39]|new[41]|giv[43]|giv[45]	_	_
6-16	767-768	.	_	_	_	_

#Text=Recently , RNA sequencing techniques have allowed the discovery of novel VSGs that also include non-coding RNAs .
7-1	769-777	Recently	_	_	_	_
7-2	778-779	,	_	_	_	_
7-3	780-783	RNA	substance|abstract[47]|abstract[48]	new|new[47]|new[48]	_	_
7-4	784-794	sequencing	abstract[47]|abstract[48]	new[47]|new[48]	_	_
7-5	795-805	techniques	abstract[48]	new[48]	_	_
7-6	806-810	have	_	_	_	_
7-7	811-818	allowed	_	_	_	_
7-8	819-822	the	abstract[49]	new[49]	_	_
7-9	823-832	discovery	abstract[49]	new[49]	_	_
7-10	833-835	of	abstract[49]	new[49]	_	_
7-11	836-841	novel	abstract[49]|abstract[50]	new[49]|giv[50]	coref	8-11[0_50]
7-12	842-846	VSGs	abstract[49]|abstract[50]	new[49]|giv[50]	_	_
7-13	847-851	that	abstract[49]|abstract[50]	new[49]|giv[50]	_	_
7-14	852-856	also	abstract[49]|abstract[50]	new[49]|giv[50]	_	_
7-15	857-864	include	abstract[49]|abstract[50]	new[49]|giv[50]	_	_
7-16	865-875	non-coding	abstract[49]|abstract[50]|abstract[51]	new[49]|giv[50]|new[51]	_	_
7-17	876-880	RNAs	abstract[49]|abstract[50]|abstract[51]	new[49]|giv[50]|new[51]	_	_
7-18	881-882	.	_	_	_	_

#Text=This Special Issue of Viruses will explore the impact of VSGs on the outcome of virus infection and the role of these genes within the infected cells and organism .
8-1	883-887	This	abstract[52]	new[52]	coref	12-2[91_52]
8-2	888-895	Special	abstract[52]	new[52]	_	_
8-3	896-901	Issue	abstract[52]	new[52]	_	_
8-4	902-904	of	abstract[52]	new[52]	_	_
8-5	905-912	Viruses	abstract[52]|abstract	new[52]|new	_	_
8-6	913-917	will	_	_	_	_
8-7	918-925	explore	_	_	_	_
8-8	926-929	the	abstract[54]	new[54]	_	_
8-9	930-936	impact	abstract[54]	new[54]	_	_
8-10	937-939	of	abstract[54]	new[54]	_	_
8-11	940-944	VSGs	abstract[54]|abstract	new[54]|giv	coref	11-11
8-12	945-947	on	abstract[54]	new[54]	_	_
8-13	948-951	the	abstract[54]|abstract[56]	new[54]|new[56]	_	_
8-14	952-959	outcome	abstract[54]|abstract[56]	new[54]|new[56]	_	_
8-15	960-962	of	abstract[54]|abstract[56]	new[54]|new[56]	_	_
8-16	963-968	virus	abstract[54]|abstract[56]|abstract|event[58]	new[54]|new[56]|giv|giv[58]	coref|coref	9-18[68_0]|10-15[78_58]
8-17	969-978	infection	abstract[54]|abstract[56]|event[58]	new[54]|new[56]|giv[58]	_	_
8-18	979-982	and	_	_	_	_
8-19	983-986	the	abstract[59]	giv[59]	_	_
8-20	987-991	role	abstract[59]	giv[59]	_	_
8-21	992-994	of	abstract[59]	giv[59]	_	_
8-22	995-1000	these	abstract[59]|abstract[60]	giv[59]|giv[60]	coref	13-26[0_60]
8-23	1001-1006	genes	abstract[59]|abstract[60]	giv[59]|giv[60]	_	_
8-24	1007-1013	within	abstract[59]	giv[59]	_	_
8-25	1014-1017	the	abstract[59]|animal[61]	giv[59]|new[61]	coref	19-8[173_61]
8-26	1018-1026	infected	abstract[59]|animal[61]	giv[59]|new[61]	_	_
8-27	1027-1032	cells	abstract[59]|animal[61]	giv[59]|new[61]	_	_
8-28	1033-1036	and	abstract[59]	giv[59]	_	_
8-29	1037-1045	organism	abstract[59]|animal	giv[59]|new	_	_
8-30	1046-1047	.	_	_	_	_

#Text=We have focused on the most recent discoveries in VSG research , including the molecular biology of related virus – host interactions .
9-1	1048-1050	We	person	giv	ana	12-6
9-2	1051-1055	have	_	_	_	_
9-3	1056-1063	focused	_	_	_	_
9-4	1064-1066	on	_	_	_	_
9-5	1067-1070	the	abstract[64]	new[64]	_	_
9-6	1071-1075	most	abstract[64]	new[64]	_	_
9-7	1076-1082	recent	abstract[64]	new[64]	_	_
9-8	1083-1094	discoveries	abstract[64]	new[64]	_	_
9-9	1095-1097	in	abstract[64]	new[64]	_	_
9-10	1098-1101	VSG	abstract[64]|abstract|abstract[66]	new[64]|new|new[66]	coref	12-30[0_66]
9-11	1102-1110	research	abstract[64]|abstract[66]	new[64]|new[66]	_	_
9-12	1111-1112	,	abstract[64]	new[64]	_	_
9-13	1113-1122	including	abstract[64]	new[64]	_	_
9-14	1123-1126	the	abstract[64]|abstract[67]	new[64]|new[67]	_	_
9-15	1127-1136	molecular	abstract[64]|abstract[67]	new[64]|new[67]	_	_
9-16	1137-1144	biology	abstract[64]|abstract[67]	new[64]|new[67]	_	_
9-17	1145-1147	of	abstract[64]|abstract[67]	new[64]|new[67]	_	_
9-18	1148-1155	related	abstract[64]|abstract[67]|abstract[68]|abstract[70]	new[64]|new[67]|giv[68]|new[70]	coref	10-15[0_68]
9-19	1156-1161	virus	abstract[64]|abstract[67]|abstract[68]|abstract[70]	new[64]|new[67]|giv[68]|new[70]	_	_
9-20	1162-1163	–	abstract[64]|abstract[67]|abstract[70]	new[64]|new[67]|new[70]	_	_
9-21	1164-1168	host	abstract[64]|abstract[67]|person|abstract[70]	new[64]|new[67]|giv|new[70]	coref	10-27
9-22	1169-1181	interactions	abstract[64]|abstract[67]|abstract[70]	new[64]|new[67]|new[70]	_	_
9-23	1182-1183	.	_	_	_	_

#Text=Topics include studies on various steps of gene induction , innate immune responses to virus infection , and the mechanisms of virus immune evasion of related host defense pathways .
10-1	1184-1190	Topics	abstract	new	_	_
10-2	1191-1198	include	_	_	_	_
10-3	1199-1206	studies	abstract[72]	new[72]	_	_
10-4	1207-1209	on	abstract[72]	new[72]	_	_
10-5	1210-1217	various	abstract[72]|abstract[73]	new[72]|new[73]	_	_
10-6	1218-1223	steps	abstract[72]|abstract[73]	new[72]|new[73]	_	_
10-7	1224-1226	of	abstract[72]|abstract[73]	new[72]|new[73]	_	_
10-8	1227-1231	gene	abstract[72]|abstract[73]|abstract|event[75]	new[72]|new[73]|new|new[75]	_	_
10-9	1232-1241	induction	abstract[72]|abstract[73]|event[75]	new[72]|new[73]|new[75]	_	_
10-10	1242-1243	,	abstract[72]|abstract[73]	new[72]|new[73]	_	_
10-11	1244-1250	innate	abstract[72]|abstract[73]|abstract[76]	new[72]|new[73]|new[76]	coref	16-16[144_76]
10-12	1251-1257	immune	abstract[72]|abstract[73]|abstract[76]	new[72]|new[73]|new[76]	_	_
10-13	1258-1267	responses	abstract[72]|abstract[73]|abstract[76]	new[72]|new[73]|new[76]	_	_
10-14	1268-1270	to	abstract[72]|abstract[73]|abstract[76]	new[72]|new[73]|new[76]	_	_
10-15	1271-1276	virus	abstract[72]|abstract[73]|abstract[76]|abstract|event[78]	new[72]|new[73]|new[76]|giv|giv[78]	coref|coref	10-22|16-10[142_78]
10-16	1277-1286	infection	abstract[72]|abstract[73]|abstract[76]|event[78]	new[72]|new[73]|new[76]|giv[78]	_	_
10-17	1287-1288	,	abstract[72]	new[72]	_	_
10-18	1289-1292	and	abstract[72]	new[72]	_	_
10-19	1293-1296	the	abstract[72]|abstract[79]	new[72]|new[79]	coref	15-5[129_79]
10-20	1297-1307	mechanisms	abstract[72]|abstract[79]	new[72]|new[79]	_	_
10-21	1308-1310	of	abstract[72]|abstract[79]	new[72]|new[79]	_	_
10-22	1311-1316	virus	abstract[72]|abstract[79]|abstract|abstract[81]	new[72]|new[79]|giv|new[81]	_	_
10-23	1317-1323	immune	abstract[72]|abstract[79]|abstract[81]	new[72]|new[79]|new[81]	_	_
10-24	1324-1331	evasion	abstract[72]|abstract[79]|abstract[81]	new[72]|new[79]|new[81]	_	_
10-25	1332-1334	of	abstract[72]|abstract[79]|abstract[81]	new[72]|new[79]|new[81]	_	_
10-26	1335-1342	related	abstract[72]|abstract[79]|abstract[81]|abstract[84]	new[72]|new[79]|new[81]|giv[84]	coref	13-14[103_84]
10-27	1343-1347	host	abstract[72]|abstract[79]|abstract[81]|person|abstract[83]|abstract[84]	new[72]|new[79]|new[81]|giv|giv[83]|giv[84]	coref|coref	23-10|23-10[227_83]
10-28	1348-1355	defense	abstract[72]|abstract[79]|abstract[81]|abstract[83]|abstract[84]	new[72]|new[79]|new[81]|giv[83]|giv[84]	_	_
10-29	1356-1364	pathways	abstract[72]|abstract[79]|abstract[81]|abstract[84]	new[72]|new[79]|new[81]|giv[84]	_	_
10-30	1365-1366	.	_	_	_	_

#Text=The clinical presentation of VSG-driven pathology and strategies to use VSGs to cure chronic viral infections are also discussed .
11-1	1367-1370	The	event[85]|person[86]	new[85]|new[86]	ana	14-1[0_86]
11-2	1371-1379	clinical	event[85]|person[86]	new[85]|new[86]	_	_
11-3	1380-1392	presentation	event[85]|person[86]	new[85]|new[86]	_	_
11-4	1393-1395	of	event[85]|person[86]	new[85]|new[86]	_	_
11-5	1396-1406	VSG-driven	event[85]|person[86]|abstract[87]	new[85]|new[86]|new[87]	_	_
11-6	1407-1416	pathology	event[85]|person[86]|abstract[87]	new[85]|new[86]|new[87]	_	_
11-7	1417-1420	and	person[86]	new[86]	_	_
11-8	1421-1431	strategies	person[86]|abstract[88]	new[86]|new[88]	coref	25-16[243_88]
11-9	1432-1434	to	person[86]|abstract[88]	new[86]|new[88]	_	_
11-10	1435-1438	use	person[86]|abstract[88]	new[86]|new[88]	_	_
11-11	1439-1443	VSGs	person[86]|abstract[88]|abstract	new[86]|new[88]|giv	coref	12-33
11-12	1444-1446	to	_	_	_	_
11-13	1447-1451	cure	_	_	_	_
11-14	1452-1459	chronic	abstract[90]	new[90]	coref	13-31[109_90]
11-15	1460-1465	viral	abstract[90]	new[90]	_	_
11-16	1466-1476	infections	abstract[90]	new[90]	_	_
11-17	1477-1480	are	_	_	_	_
11-18	1481-1485	also	_	_	_	_
11-19	1486-1495	discussed	_	_	_	_
11-20	1496-1497	.	_	_	_	_

#Text=In this special Issue , we endeavored to assemble a collection of research papers and reviews that , together , will offer a comprehensive view on new areas of research pertaining to VSGs .
12-1	1498-1500	In	_	_	_	_
12-2	1501-1505	this	abstract[91]	giv[91]	coref	26-3[245_91]
12-3	1506-1513	special	abstract[91]	giv[91]	_	_
12-4	1514-1519	Issue	abstract[91]	giv[91]	_	_
12-5	1520-1521	,	_	_	_	_
12-6	1522-1524	we	person	giv	ana	23-6
12-7	1525-1535	endeavored	_	_	_	_
12-8	1536-1538	to	_	_	_	_
12-9	1539-1547	assemble	_	_	_	_
12-10	1548-1549	a	abstract[93]	new[93]	_	_
12-11	1550-1560	collection	abstract[93]	new[93]	_	_
12-12	1561-1563	of	abstract[93]	new[93]	_	_
12-13	1564-1572	research	abstract[93]|abstract[94]	new[93]|new[94]	_	_
12-14	1573-1579	papers	abstract[93]|abstract[94]	new[93]|new[94]	_	_
12-15	1580-1583	and	abstract[93]	new[93]	_	_
12-16	1584-1591	reviews	abstract[93]|abstract[95]	new[93]|new[95]	_	_
12-17	1592-1596	that	abstract[93]|abstract[95]	new[93]|new[95]	_	_
12-18	1597-1598	,	abstract[93]|abstract[95]	new[93]|new[95]	_	_
12-19	1599-1607	together	abstract[93]|abstract[95]	new[93]|new[95]	_	_
12-20	1608-1609	,	abstract[93]|abstract[95]	new[93]|new[95]	_	_
12-21	1610-1614	will	abstract[93]|abstract[95]	new[93]|new[95]	_	_
12-22	1615-1620	offer	abstract[93]|abstract[95]	new[93]|new[95]	_	_
12-23	1621-1622	a	abstract[93]|abstract[95]|abstract[96]	new[93]|new[95]|new[96]	_	_
12-24	1623-1636	comprehensive	abstract[93]|abstract[95]|abstract[96]	new[93]|new[95]|new[96]	_	_
12-25	1637-1641	view	abstract[93]|abstract[95]|abstract[96]	new[93]|new[95]|new[96]	_	_
12-26	1642-1644	on	abstract[93]|abstract[95]|abstract[96]	new[93]|new[95]|new[96]	_	_
12-27	1645-1648	new	abstract[93]|abstract[95]|abstract[96]|abstract[97]	new[93]|new[95]|new[96]|new[97]	_	_
12-28	1649-1654	areas	abstract[93]|abstract[95]|abstract[96]|abstract[97]	new[93]|new[95]|new[96]|new[97]	_	_
12-29	1655-1657	of	abstract[93]|abstract[95]|abstract[96]|abstract[97]	new[93]|new[95]|new[96]|new[97]	_	_
12-30	1658-1666	research	abstract[93]|abstract[95]|abstract[96]|abstract[97]|abstract	new[93]|new[95]|new[96]|new[97]|giv	_	_
12-31	1667-1677	pertaining	abstract[93]|abstract[95]|abstract[96]|abstract[97]	new[93]|new[95]|new[96]|new[97]	_	_
12-32	1678-1680	to	abstract[93]|abstract[95]|abstract[96]|abstract[97]	new[93]|new[95]|new[96]|new[97]	_	_
12-33	1681-1685	VSGs	abstract[93]|abstract[95]|abstract[96]|abstract[97]|abstract	new[93]|new[95]|new[96]|new[97]|giv	coref	13-28
12-34	1686-1687	.	_	_	_	_

#Text=Majzoub et al. contributed an exciting review , addressing the current knowledge of the innate immune pathways involved in sensing , signaling , and inducing ISGs and VSGs to counter viral infections .
13-1	1688-1695	Majzoub	person	new	_	_
13-2	1696-1698	et	_	_	_	_
13-3	1699-1702	al.	_	_	_	_
13-4	1703-1714	contributed	_	_	_	_
13-5	1715-1717	an	abstract[101]	new[101]	_	_
13-6	1718-1726	exciting	abstract[101]	new[101]	_	_
13-7	1727-1733	review	abstract[101]	new[101]	_	_
13-8	1734-1735	,	_	_	_	_
13-9	1736-1746	addressing	_	_	_	_
13-10	1747-1750	the	abstract[102]	new[102]	_	_
13-11	1751-1758	current	abstract[102]	new[102]	_	_
13-12	1759-1768	knowledge	abstract[102]	new[102]	_	_
13-13	1769-1771	of	abstract[102]	new[102]	_	_
13-14	1772-1775	the	abstract[102]|abstract[103]	new[102]|giv[103]	coref	14-37[126_103]
13-15	1776-1782	innate	abstract[102]|abstract[103]	new[102]|giv[103]	_	_
13-16	1783-1789	immune	abstract[102]|abstract[103]	new[102]|giv[103]	_	_
13-17	1790-1798	pathways	abstract[102]|abstract[103]	new[102]|giv[103]	_	_
13-18	1799-1807	involved	abstract[102]|abstract[103]	new[102]|giv[103]	_	_
13-19	1808-1810	in	_	_	_	_
13-20	1811-1818	sensing	place	new	_	_
13-21	1819-1820	,	_	_	_	_
13-22	1821-1830	signaling	abstract	giv	coref	18-9
13-23	1831-1832	,	_	_	_	_
13-24	1833-1836	and	_	_	_	_
13-25	1837-1845	inducing	_	_	_	_
13-26	1846-1850	ISGs	abstract|abstract[107]	giv|giv[107]	coref|coref	13-26[107_0]|19-27[180_107]
13-27	1851-1854	and	abstract[107]	giv[107]	_	_
13-28	1855-1859	VSGs	abstract[107]|abstract	giv[107]|giv	coref	16-20
13-29	1860-1862	to	_	_	_	_
13-30	1863-1870	counter	_	_	_	_
13-31	1871-1876	viral	abstract[109]	giv[109]	coref	14-42[127_109]
13-32	1877-1887	infections	abstract[109]	giv[109]	_	_
13-33	1888-1889	.	_	_	_	_

#Text=Their manuscript specifically discussed Toll-like receptors ( TLRs ) , RIG-I-like receptors ( RLRs ) , and the cGAS-STING pathway , placing their evolution into perspective in diverse organisms and the dynamic co-evolution and diversification of these pathways with respect to viral infections .
14-1	1890-1895	Their	person|abstract[111]	giv|new[111]	ana	14-23
14-2	1896-1906	manuscript	abstract[111]	new[111]	_	_
14-3	1907-1919	specifically	_	_	_	_
14-4	1920-1929	discussed	_	_	_	_
14-5	1930-1939	Toll-like	abstract|abstract[113]	new|new[113]	appos	14-8[0_113]
14-6	1940-1949	receptors	abstract[113]	new[113]	_	_
14-7	1950-1951	(	_	_	_	_
14-8	1952-1956	TLRs	abstract	giv	_	_
14-9	1957-1958	)	_	_	_	_
14-10	1959-1960	,	_	_	_	_
14-11	1961-1971	RIG-I-like	abstract|abstract[116]	new|new[116]	appos	14-14[0_116]
14-12	1972-1981	receptors	abstract[116]	new[116]	_	_
14-13	1982-1983	(	_	_	_	_
14-14	1984-1988	RLRs	abstract	giv	coref	15-14[133_0]
14-15	1989-1990	)	_	_	_	_
14-16	1991-1992	,	_	_	_	_
14-17	1993-1996	and	_	_	_	_
14-18	1997-2000	the	abstract[119]	new[119]	_	_
14-19	2001-2011	cGAS-STING	abstract|abstract[119]	new|new[119]	_	_
14-20	2012-2019	pathway	abstract[119]	new[119]	_	_
14-21	2020-2021	,	_	_	_	_
14-22	2022-2029	placing	_	_	_	_
14-23	2030-2035	their	person|abstract[121]	giv|new[121]	_	_
14-24	2036-2045	evolution	abstract[121]	new[121]	_	_
14-25	2046-2050	into	_	_	_	_
14-26	2051-2062	perspective	abstract	new	_	_
14-27	2063-2065	in	_	_	_	_
14-28	2066-2073	diverse	animal[123]	new[123]	_	_
14-29	2074-2083	organisms	animal[123]	new[123]	_	_
14-30	2084-2087	and	_	_	_	_
14-31	2088-2091	the	abstract[124]	new[124]	_	_
14-32	2092-2099	dynamic	abstract[124]	new[124]	_	_
14-33	2100-2112	co-evolution	abstract[124]	new[124]	_	_
14-34	2113-2116	and	_	_	_	_
14-35	2117-2132	diversification	abstract[125]	new[125]	_	_
14-36	2133-2135	of	abstract[125]	new[125]	_	_
14-37	2136-2141	these	abstract[125]|abstract[126]	new[125]|giv[126]	coref	18-8[165_126]
14-38	2142-2150	pathways	abstract[125]|abstract[126]	new[125]|giv[126]	_	_
14-39	2151-2155	with	abstract[125]	new[125]	_	_
14-40	2156-2163	respect	abstract[125]	new[125]	_	_
14-41	2164-2166	to	abstract[125]	new[125]	_	_
14-42	2167-2172	viral	abstract[125]|abstract[127]	new[125]|giv[127]	_	_
14-43	2173-2183	infections	abstract[125]|abstract[127]	new[125]|giv[127]	_	_
14-44	2184-2185	.	_	_	_	_

#Text=Liu et al. discussed the mechanisms underlying how herpesviruses can be detected by pattern recognition receptors ( PRRs ) to induce the expression of interferons ( IFNs ) and inflammatory cytokines .
15-1	2186-2189	Liu	person	new	_	_
15-2	2190-2192	et	_	_	_	_
15-3	2193-2196	al.	_	_	_	_
15-4	2197-2206	discussed	_	_	_	_
15-5	2207-2210	the	abstract[129]	giv[129]	_	_
15-6	2211-2221	mechanisms	abstract[129]	giv[129]	_	_
15-7	2222-2232	underlying	abstract[129]	giv[129]	_	_
15-8	2233-2236	how	abstract[129]	giv[129]	_	_
15-9	2237-2250	herpesviruses	abstract[129]|animal	giv[129]|new	coref	16-7
15-10	2251-2254	can	abstract[129]	giv[129]	_	_
15-11	2255-2257	be	abstract[129]	giv[129]	_	_
15-12	2258-2266	detected	abstract[129]	giv[129]	_	_
15-13	2267-2269	by	abstract[129]	giv[129]	_	_
15-14	2270-2277	pattern	abstract[129]|abstract|abstract[132]|abstract[133]	giv[129]|new|new[132]|giv[133]	appos	15-18[0_133]
15-15	2278-2289	recognition	abstract[129]|abstract[132]|abstract[133]	giv[129]|new[132]|giv[133]	_	_
15-16	2290-2299	receptors	abstract[129]|abstract[133]	giv[129]|giv[133]	_	_
15-17	2300-2301	(	abstract[129]	giv[129]	_	_
15-18	2302-2306	PRRs	abstract[129]|abstract	giv[129]|giv	_	_
15-19	2307-2308	)	abstract[129]	giv[129]	_	_
15-20	2309-2311	to	abstract[129]	giv[129]	_	_
15-21	2312-2318	induce	abstract[129]	giv[129]	_	_
15-22	2319-2322	the	abstract[129]|abstract[135]	giv[129]|new[135]	coref	18-15[166_135]
15-23	2323-2333	expression	abstract[129]|abstract[135]	giv[129]|new[135]	_	_
15-24	2334-2336	of	abstract[129]|abstract[135]	giv[129]|new[135]	_	_
15-25	2337-2348	interferons	abstract[129]|abstract[135]|abstract	giv[129]|new[135]|new	appos	15-27
15-26	2349-2350	(	_	_	_	_
15-27	2351-2355	IFNs	abstract	giv	ana	16-1
15-28	2356-2357	)	_	_	_	_
15-29	2358-2361	and	_	_	_	_
15-30	2362-2374	inflammatory	abstract[138]	new[138]	_	_
15-31	2375-2384	cytokines	abstract[138]	new[138]	_	_
15-32	2385-2386	.	_	_	_	_

#Text=They also described the ability of herpesviruses to establish persistent infection in the presence of active immune responses involving VSGs .
16-1	2387-2391	They	abstract	giv	_	_
16-2	2392-2396	also	_	_	_	_
16-3	2397-2406	described	_	_	_	_
16-4	2407-2410	the	abstract[140]	new[140]	_	_
16-5	2411-2418	ability	abstract[140]	new[140]	_	_
16-6	2419-2421	of	abstract[140]	new[140]	_	_
16-7	2422-2435	herpesviruses	abstract[140]|animal	new[140]|giv	_	_
16-8	2436-2438	to	abstract[140]	new[140]	_	_
16-9	2439-2448	establish	abstract[140]	new[140]	_	_
16-10	2449-2459	persistent	abstract[140]|event[142]	new[140]|giv[142]	coref	17-26[155_142]
16-11	2460-2469	infection	abstract[140]|event[142]	new[140]|giv[142]	_	_
16-12	2470-2472	in	abstract[140]	new[140]	_	_
16-13	2473-2476	the	abstract[140]|abstract[143]	new[140]|new[143]	_	_
16-14	2477-2485	presence	abstract[140]|abstract[143]	new[140]|new[143]	_	_
16-15	2486-2488	of	abstract[140]|abstract[143]	new[140]|new[143]	_	_
16-16	2489-2495	active	abstract[140]|abstract[143]|abstract[144]	new[140]|new[143]|giv[144]	coref	23-9[228_144]
16-17	2496-2502	immune	abstract[140]|abstract[143]|abstract[144]	new[140]|new[143]|giv[144]	_	_
16-18	2503-2512	responses	abstract[140]|abstract[143]|abstract[144]	new[140]|new[143]|giv[144]	_	_
16-19	2513-2522	involving	abstract[140]|abstract[143]|abstract[144]	new[140]|new[143]|giv[144]	_	_
16-20	2523-2527	VSGs	abstract[140]|abstract[143]|abstract[144]|abstract	new[140]|new[143]|giv[144]|giv	_	_
16-21	2528-2529	.	_	_	_	_

#Text=Asmi et al. reviewed Small Ubiquitin-like Modifier ( SUMO ) protein conjugation as a component of intrinsic and innate immunity , specifically with respect to rhabdoviruses infection and in relation to the production and secretion of interferon .
17-1	2530-2534	Asmi	person	new	_	_
17-2	2535-2537	et	_	_	_	_
17-3	2538-2541	al.	_	_	_	_
17-4	2542-2550	reviewed	_	_	_	_
17-5	2551-2556	Small	abstract[151]	new[151]	_	_
17-6	2557-2571	Ubiquitin-like	abstract|abstract[148]|abstract[151]	new|new[148]|new[151]	appos	17-9[0_148]
17-7	2572-2580	Modifier	abstract[148]|abstract[151]	new[148]|new[151]	_	_
17-8	2581-2582	(	abstract[151]	new[151]	_	_
17-9	2583-2587	SUMO	abstract|abstract[151]	giv|new[151]	_	_
17-10	2588-2589	)	abstract[151]	new[151]	_	_
17-11	2590-2597	protein	substance|abstract[151]	new|new[151]	_	_
17-12	2598-2609	conjugation	abstract[151]	new[151]	_	_
17-13	2610-2612	as	_	_	_	_
17-14	2613-2614	a	abstract[152]	new[152]	_	_
17-15	2615-2624	component	abstract[152]	new[152]	_	_
17-16	2625-2627	of	abstract[152]	new[152]	_	_
17-17	2628-2637	intrinsic	abstract[152]|abstract[153]	new[152]|new[153]	_	_
17-18	2638-2641	and	abstract[152]|abstract[153]	new[152]|new[153]	_	_
17-19	2642-2648	innate	abstract[152]|abstract[153]	new[152]|new[153]	_	_
17-20	2649-2657	immunity	abstract[152]|abstract[153]	new[152]|new[153]	_	_
17-21	2658-2659	,	_	_	_	_
17-22	2660-2672	specifically	_	_	_	_
17-23	2673-2677	with	_	_	_	_
17-24	2678-2685	respect	_	_	_	_
17-25	2686-2688	to	_	_	_	_
17-26	2689-2702	rhabdoviruses	animal|event[155]	new|giv[155]	coref	19-35[184_155]
17-27	2703-2712	infection	event[155]	giv[155]	_	_
17-28	2713-2716	and	_	_	_	_
17-29	2717-2719	in	_	_	_	_
17-30	2720-2728	relation	_	_	_	_
17-31	2729-2731	to	_	_	_	_
17-32	2732-2735	the	abstract[156]	new[156]	coref	18-1[161_156]
17-33	2736-2746	production	abstract[156]	new[156]	_	_
17-34	2747-2750	and	_	_	_	_
17-35	2751-2760	secretion	abstract[157]	new[157]	_	_
17-36	2761-2763	of	abstract[157]	new[157]	_	_
17-37	2764-2774	interferon	abstract[157]|organization	new[157]|giv	coref	18-2
17-38	2775-2776	.	_	_	_	_

#Text=Rhabdoviruses-induced interferon production and the activation of interferon signaling pathways , as well as the expression and functions of viral restriction factors , are discussed .
18-1	2777-2798	Rhabdoviruses-induced	object|abstract[161]	new|giv[161]	coref	19-18[175_161]
18-2	2799-2809	interferon	organization|abstract[161]	giv|giv[161]	coref	18-8
18-3	2810-2820	production	abstract[161]	giv[161]	_	_
18-4	2821-2824	and	_	_	_	_
18-5	2825-2828	the	event[162]	new[162]	coref	21-31[209_162]
18-6	2829-2839	activation	event[162]	new[162]	_	_
18-7	2840-2842	of	event[162]	new[162]	_	_
18-8	2843-2853	interferon	event[162]|organization|abstract[165]	new[162]|giv|giv[165]	_	_
18-9	2854-2863	signaling	event[162]|abstract|abstract[165]	new[162]|giv|giv[165]	coref	26-25[251_0]
18-10	2864-2872	pathways	event[162]|abstract[165]	new[162]|giv[165]	_	_
18-11	2873-2874	,	_	_	_	_
18-12	2875-2877	as	_	_	_	_
18-13	2878-2882	well	_	_	_	_
18-14	2883-2885	as	_	_	_	_
18-15	2886-2889	the	abstract[166]	giv[166]	coref	21-18[204_166]
18-16	2890-2900	expression	abstract[166]	giv[166]	_	_
18-17	2901-2904	and	_	_	_	_
18-18	2905-2914	functions	abstract[167]	new[167]	_	_
18-19	2915-2917	of	abstract[167]	new[167]	_	_
18-20	2918-2923	viral	abstract[167]|abstract[169]	new[167]|new[169]	_	_
18-21	2924-2935	restriction	abstract[167]|abstract|abstract[169]	new[167]|new|new[169]	_	_
18-22	2936-2943	factors	abstract[167]|abstract[169]	new[167]|new[169]	_	_
18-23	2944-2945	,	_	_	_	_
18-24	2946-2949	are	_	_	_	_
18-25	2950-2959	discussed	_	_	_	_
18-26	2960-2961	.	_	_	_	_

#Text=Ashley et al. reported that by using cells engineered to block either the response to , or production of , type-I IFN , the regulation of IFN-independent ISGs was examined in the context of human cytomegalovirus ( HCMV ) infection .
19-1	2962-2968	Ashley	person|person[171]	new|new[171]	ana|ana	21-10[0_171]|22-3
19-2	2969-2971	et	person[171]	new[171]	_	_
19-3	2972-2975	al.	person[171]|person	new[171]|new	coref	22-5
19-4	2976-2984	reported	_	_	_	_
19-5	2985-2989	that	_	_	_	_
19-6	2990-2992	by	_	_	_	_
19-7	2993-2998	using	_	_	_	_
19-8	2999-3004	cells	animal[173]	giv[173]	_	_
19-9	3005-3015	engineered	animal[173]	giv[173]	_	_
19-10	3016-3018	to	animal[173]	giv[173]	_	_
19-11	3019-3024	block	animal[173]	giv[173]	_	_
19-12	3025-3031	either	animal[173]|event[174]	giv[173]|new[174]	_	_
19-13	3032-3035	the	animal[173]|event[174]	giv[173]|new[174]	_	_
19-14	3036-3044	response	animal[173]|event[174]	giv[173]|new[174]	_	_
19-15	3045-3047	to	animal[173]	giv[173]	_	_
19-16	3048-3049	,	animal[173]	giv[173]	_	_
19-17	3050-3052	or	animal[173]	giv[173]	_	_
19-18	3053-3063	production	animal[173]|abstract[175]	giv[173]|giv[175]	coref	22-19[218_175]
19-19	3064-3066	of	animal[173]|abstract[175]	giv[173]|giv[175]	_	_
19-20	3067-3068	,	animal[173]|abstract[175]	giv[173]|giv[175]	_	_
19-21	3069-3075	type-I	animal[173]|abstract[175]|abstract|abstract[177]	giv[173]|giv[175]|new|giv[177]	coref|coref	20-30|20-30[196_177]
19-22	3076-3079	IFN	animal[173]|abstract[175]|abstract[177]	giv[173]|giv[175]|giv[177]	_	_
19-23	3080-3081	,	_	_	_	_
19-24	3082-3085	the	abstract[178]	new[178]	_	_
19-25	3086-3096	regulation	abstract[178]	new[178]	_	_
19-26	3097-3099	of	abstract[178]	new[178]	_	_
19-27	3100-3115	IFN-independent	abstract[178]|abstract|abstract[180]	new[178]|new|giv[180]	coref	20-1[185_180]
19-28	3116-3120	ISGs	abstract[178]|abstract[180]	new[178]|giv[180]	_	_
19-29	3121-3124	was	_	_	_	_
19-30	3125-3133	examined	_	_	_	_
19-31	3134-3136	in	_	_	_	_
19-32	3137-3140	the	abstract[181]	new[181]	_	_
19-33	3141-3148	context	abstract[181]	new[181]	_	_
19-34	3149-3151	of	abstract[181]	new[181]	_	_
19-35	3152-3157	human	abstract[181]|substance[182]|event[184]	new[181]|new[182]|giv[184]	coref	20-26[194_184]
19-36	3158-3173	cytomegalovirus	abstract[181]|substance[182]|event[184]	new[181]|new[182]|giv[184]	_	_
19-37	3174-3175	(	abstract[181]|event[184]	new[181]|giv[184]	_	_
19-38	3176-3180	HCMV	abstract[181]|object|event[184]	new[181]|new|giv[184]	coref	20-26
19-39	3181-3182	)	abstract[181]|event[184]	new[181]|giv[184]	_	_
19-40	3183-3192	infection	abstract[181]|event[184]	new[181]|giv[184]	_	_
19-41	3193-3194	.	_	_	_	_

#Text=Several ISGs , including IFIT1 , IFIT2 , IFIT3 , Mx1 , Mx2 , CXCL10 , and ISG15 were found to be upregulated transcriptionally following HCMV infection independently of type-I IFN .
20-1	3195-3202	Several	abstract[185]	giv[185]	coref	24-16[237_185]
20-2	3203-3207	ISGs	abstract[185]	giv[185]	_	_
20-3	3208-3209	,	abstract[185]	giv[185]	_	_
20-4	3210-3219	including	abstract[185]	giv[185]	_	_
20-5	3220-3225	IFIT1	abstract[185]|abstract	giv[185]|new	_	_
20-6	3226-3227	,	abstract[185]	giv[185]	_	_
20-7	3228-3233	IFIT2	abstract[185]|abstract	giv[185]|new	_	_
20-8	3234-3235	,	abstract[185]	giv[185]	_	_
20-9	3236-3241	IFIT3	abstract[185]|abstract	giv[185]|new	_	_
20-10	3242-3243	,	abstract[185]	giv[185]	_	_
20-11	3244-3247	Mx1	abstract[185]|abstract	giv[185]|new	_	_
20-12	3248-3249	,	abstract[185]	giv[185]	_	_
20-13	3250-3253	Mx2	abstract[185]|abstract	giv[185]|new	_	_
20-14	3254-3255	,	abstract[185]	giv[185]	_	_
20-15	3256-3262	CXCL10	abstract[185]|abstract	giv[185]|new	_	_
20-16	3263-3264	,	abstract[185]	giv[185]	_	_
20-17	3265-3268	and	abstract[185]	giv[185]	_	_
20-18	3269-3274	ISG15	abstract[185]|abstract	giv[185]|new	_	_
20-19	3275-3279	were	_	_	_	_
20-20	3280-3285	found	_	_	_	_
20-21	3286-3288	to	_	_	_	_
20-22	3289-3291	be	_	_	_	_
20-23	3292-3303	upregulated	_	_	_	_
20-24	3304-3321	transcriptionally	_	_	_	_
20-25	3322-3331	following	_	_	_	_
20-26	3332-3336	HCMV	object|event[194]	giv|giv[194]	coref|coref	21-21|21-21[206_194]
20-27	3337-3346	infection	event[194]	giv[194]	_	_
20-28	3347-3360	independently	_	_	_	_
20-29	3361-3363	of	_	_	_	_
20-30	3364-3370	type-I	abstract|abstract[196]	giv|giv[196]	coref|coref	22-19|22-20[0_196]
20-31	3371-3374	IFN	abstract[196]	giv[196]	_	_
20-32	3375-3376	.	_	_	_	_

#Text=Furthermore , by using IRF3 knockdown CRISPR/Cas-9 clones , they were able to demonstrate IFN-independent control of ISG expression during HCMV infection of human fibroblasts that is absolutely dependent on IRF3 activation .
21-1	3377-3388	Furthermore	_	_	_	_
21-2	3389-3390	,	_	_	_	_
21-3	3391-3393	by	_	_	_	_
21-4	3394-3399	using	_	_	_	_
21-5	3400-3404	IRF3	abstract|event[198]|abstract[200]	giv|new[198]|new[200]	coref	21-31
21-6	3405-3414	knockdown	event[198]|abstract[200]	new[198]|new[200]	_	_
21-7	3415-3427	CRISPR/Cas-9	abstract|abstract[200]	new|new[200]	_	_
21-8	3428-3434	clones	abstract[200]	new[200]	_	_
21-9	3435-3436	,	_	_	_	_
21-10	3437-3441	they	person	giv	_	_
21-11	3442-3446	were	_	_	_	_
21-12	3447-3451	able	_	_	_	_
21-13	3452-3454	to	_	_	_	_
21-14	3455-3466	demonstrate	_	_	_	_
21-15	3467-3482	IFN-independent	abstract[202]	new[202]	_	_
21-16	3483-3490	control	abstract[202]	new[202]	_	_
21-17	3491-3493	of	abstract[202]	new[202]	_	_
21-18	3494-3497	ISG	abstract[202]|abstract|abstract[204]	new[202]|new|giv[204]	_	_
21-19	3498-3508	expression	abstract[202]|abstract[204]	new[202]|giv[204]	_	_
21-20	3509-3515	during	abstract[202]|abstract[204]	new[202]|giv[204]	_	_
21-21	3516-3520	HCMV	abstract[202]|abstract[204]|object|event[206]	new[202]|giv[204]|giv|giv[206]	_	_
21-22	3521-3530	infection	abstract[202]|abstract[204]|event[206]	new[202]|giv[204]|giv[206]	_	_
21-23	3531-3533	of	abstract[202]|abstract[204]|event[206]	new[202]|giv[204]|giv[206]	_	_
21-24	3534-3539	human	abstract[202]|abstract[204]|event[206]|animal[207]	new[202]|giv[204]|giv[206]|new[207]	_	_
21-25	3540-3551	fibroblasts	abstract[202]|abstract[204]|event[206]|animal[207]	new[202]|giv[204]|giv[206]|new[207]	_	_
21-26	3552-3556	that	abstract[202]	new[202]	_	_
21-27	3557-3559	is	abstract[202]	new[202]	_	_
21-28	3560-3570	absolutely	abstract[202]	new[202]	_	_
21-29	3571-3580	dependent	abstract[202]	new[202]	_	_
21-30	3581-3583	on	abstract[202]	new[202]	_	_
21-31	3584-3588	IRF3	abstract[202]|abstract|event[209]	new[202]|giv|giv[209]	coref|coref	22-30|22-30[222_209]
21-32	3589-3599	activation	abstract[202]|event[209]	new[202]|giv[209]	_	_
21-33	3600-3601	.	_	_	_	_

#Text=Finally , He et al. revealed that the THO complex subunit 7 homolog ( THOC7 ) negatively regulates type-I IFN production by promoting TBK1 proteasomal degradation that subsequently decreases IRF3 activation .
22-1	3602-3609	Finally	_	_	_	_
22-2	3610-3611	,	_	_	_	_
22-3	3612-3614	He	person	giv	_	_
22-4	3615-3617	et	_	_	_	_
22-5	3618-3621	al.	person	giv	_	_
22-6	3622-3630	revealed	_	_	_	_
22-7	3631-3635	that	_	_	_	_
22-8	3636-3639	the	abstract[214]	new[214]	appos	22-15[0_214]
22-9	3640-3643	THO	abstract|abstract[213]|abstract[214]	new|new[213]|new[214]	_	_
22-10	3644-3651	complex	abstract[213]|abstract[214]	new[213]|new[214]	_	_
22-11	3652-3659	subunit	abstract[213]|abstract[214]	new[213]|new[214]	_	_
22-12	3660-3661	7	abstract[213]|abstract[214]	new[213]|new[214]	_	_
22-13	3662-3669	homolog	abstract[214]	new[214]	_	_
22-14	3670-3671	(	_	_	_	_
22-15	3672-3677	THOC7	abstract	giv	_	_
22-16	3678-3679	)	_	_	_	_
22-17	3680-3690	negatively	_	_	_	_
22-18	3691-3700	regulates	_	_	_	_
22-19	3701-3707	type-I	abstract|abstract[218]	giv|giv[218]	_	_
22-20	3708-3711	IFN	abstract|abstract[218]	giv|giv[218]	coref	24-3
22-21	3712-3722	production	abstract[218]	giv[218]	_	_
22-22	3723-3725	by	_	_	_	_
22-23	3726-3735	promoting	_	_	_	_
22-24	3736-3740	TBK1	abstract|event[220]	new|new[220]	_	_
22-25	3741-3752	proteasomal	event[220]	new[220]	_	_
22-26	3753-3764	degradation	event[220]	new[220]	_	_
22-27	3765-3769	that	event[220]	new[220]	_	_
22-28	3770-3782	subsequently	event[220]	new[220]	_	_
22-29	3783-3792	decreases	event[220]	new[220]	_	_
22-30	3793-3797	IRF3	event[220]|abstract|event[222]	new[220]|giv|giv[222]	_	_
22-31	3798-3808	activation	event[220]|event[222]	new[220]|giv[222]	_	_
22-32	3809-3810	.	_	_	_	_

#Text=Despite the recent progress in our understanding of these host defense responses , much more is left to be unraveled with respect to the regulation of antiviral responses triggered by distinct viral species .
23-1	3811-3818	Despite	_	_	_	_
23-2	3819-3822	the	abstract[223]	new[223]	_	_
23-3	3823-3829	recent	abstract[223]	new[223]	_	_
23-4	3830-3838	progress	abstract[223]	new[223]	_	_
23-5	3839-3841	in	abstract[223]	new[223]	_	_
23-6	3842-3845	our	abstract[223]|person|abstract[225]	new[223]|giv|new[225]	ana	26-1
23-7	3846-3859	understanding	abstract[223]|abstract[225]	new[223]|new[225]	_	_
23-8	3860-3862	of	abstract[223]|abstract[225]	new[223]|new[225]	_	_
23-9	3863-3868	these	abstract[223]|abstract[225]|abstract[228]	new[223]|new[225]|giv[228]	coref	23-27[230_228]
23-10	3869-3873	host	abstract[223]|abstract[225]|person|abstract[227]|abstract[228]	new[223]|new[225]|giv|giv[227]|giv[228]	coref|coref	24-9|24-9[235_227]
23-11	3874-3881	defense	abstract[223]|abstract[225]|abstract[227]|abstract[228]	new[223]|new[225]|giv[227]|giv[228]	_	_
23-12	3882-3891	responses	abstract[223]|abstract[225]|abstract[228]	new[223]|new[225]|giv[228]	_	_
23-13	3892-3893	,	_	_	_	_
23-14	3894-3898	much	_	_	_	_
23-15	3899-3903	more	_	_	_	_
23-16	3904-3906	is	_	_	_	_
23-17	3907-3911	left	_	_	_	_
23-18	3912-3914	to	_	_	_	_
23-19	3915-3917	be	_	_	_	_
23-20	3918-3927	unraveled	_	_	_	_
23-21	3928-3932	with	_	_	_	_
23-22	3933-3940	respect	_	_	_	_
23-23	3941-3943	to	_	_	_	_
23-24	3944-3947	the	abstract[229]	new[229]	_	_
23-25	3948-3958	regulation	abstract[229]	new[229]	_	_
23-26	3959-3961	of	abstract[229]	new[229]	_	_
23-27	3962-3971	antiviral	abstract[229]|abstract[230]	new[229]|giv[230]	coref	24-9[236_230]
23-28	3972-3981	responses	abstract[229]|abstract[230]	new[229]|giv[230]	_	_
23-29	3982-3991	triggered	abstract[229]|abstract[230]	new[229]|giv[230]	_	_
23-30	3992-3994	by	abstract[229]|abstract[230]	new[229]|giv[230]	_	_
23-31	3995-4003	distinct	abstract[229]|abstract[230]|animal[231]	new[229]|giv[230]|new[231]	_	_
23-32	4004-4009	viral	abstract[229]|abstract[230]|animal[231]	new[229]|giv[230]|new[231]	_	_
23-33	4010-4017	species	abstract[229]|abstract[230]|animal[231]	new[229]|giv[230]|new[231]	_	_
23-34	4018-4019	.	_	_	_	_

#Text=Clearly , IFN is a major component of host defense responses , but there are many ISGs whose antiviral activities remain to be clarified that can be regulated independently of IFN .
24-1	4020-4027	Clearly	_	_	_	_
24-2	4028-4029	,	_	_	_	_
24-3	4030-4033	IFN	abstract	giv	coref	24-5[233_0]
24-4	4034-4036	is	_	_	_	_
24-5	4037-4038	a	abstract[233]	giv[233]	coref	24-31[0_233]
24-6	4039-4044	major	abstract[233]	giv[233]	_	_
24-7	4045-4054	component	abstract[233]	giv[233]	_	_
24-8	4055-4057	of	abstract[233]	giv[233]	_	_
24-9	4058-4062	host	abstract[233]|person|abstract[235]|abstract[236]	giv[233]|giv|giv[235]|giv[236]	_	_
24-10	4063-4070	defense	abstract[233]|abstract[235]|abstract[236]	giv[233]|giv[235]|giv[236]	_	_
24-11	4071-4080	responses	abstract[233]|abstract[236]	giv[233]|giv[236]	_	_
24-12	4081-4082	,	_	_	_	_
24-13	4083-4086	but	_	_	_	_
24-14	4087-4092	there	_	_	_	_
24-15	4093-4096	are	_	_	_	_
24-16	4097-4101	many	abstract[237]	giv[237]	coref	25-1[240_237]
24-17	4102-4106	ISGs	abstract[237]	giv[237]	_	_
24-18	4107-4112	whose	abstract[237]|abstract[238]	giv[237]|giv[238]	_	_
24-19	4113-4122	antiviral	abstract[237]|abstract[238]	giv[237]|giv[238]	_	_
24-20	4123-4133	activities	abstract[237]|abstract[238]	giv[237]|giv[238]	_	_
24-21	4134-4140	remain	abstract[237]	giv[237]	_	_
24-22	4141-4143	to	abstract[237]	giv[237]	_	_
24-23	4144-4146	be	abstract[237]	giv[237]	_	_
24-24	4147-4156	clarified	abstract[237]	giv[237]	_	_
24-25	4157-4161	that	abstract[237]	giv[237]	_	_
24-26	4162-4165	can	abstract[237]	giv[237]	_	_
24-27	4166-4168	be	abstract[237]	giv[237]	_	_
24-28	4169-4178	regulated	abstract[237]	giv[237]	_	_
24-29	4179-4192	independently	abstract[237]	giv[237]	_	_
24-30	4193-4195	of	abstract[237]	giv[237]	_	_
24-31	4196-4199	IFN	abstract[237]|abstract	giv[237]|giv	coref	26-25
24-32	4200-4201	.	_	_	_	_

#Text=These new genes would likely be ideal candidates to be targeted through therapeutic intervention as novel antiviral strategies .
25-1	4202-4207	These	abstract[240]	giv[240]	coref	25-7[241_240]
25-2	4208-4211	new	abstract[240]	giv[240]	_	_
25-3	4212-4217	genes	abstract[240]	giv[240]	_	_
25-4	4218-4223	would	_	_	_	_
25-5	4224-4230	likely	_	_	_	_
25-6	4231-4233	be	_	_	_	_
25-7	4234-4239	ideal	abstract[241]	giv[241]	coref	26-19[249_241]
25-8	4240-4250	candidates	abstract[241]	giv[241]	_	_
25-9	4251-4253	to	abstract[241]	giv[241]	_	_
25-10	4254-4256	be	abstract[241]	giv[241]	_	_
25-11	4257-4265	targeted	abstract[241]	giv[241]	_	_
25-12	4266-4273	through	abstract[241]	giv[241]	_	_
25-13	4274-4285	therapeutic	abstract[241]|event[242]	giv[241]|new[242]	_	_
25-14	4286-4298	intervention	abstract[241]|event[242]	giv[241]|new[242]	_	_
25-15	4299-4301	as	abstract[241]	giv[241]	_	_
25-16	4302-4307	novel	abstract[241]|abstract[243]	giv[241]|giv[243]	_	_
25-17	4308-4317	antiviral	abstract[241]|abstract[243]	giv[241]|giv[243]	_	_
25-18	4318-4328	strategies	abstract[241]|abstract[243]	giv[241]|giv[243]	_	_
25-19	4329-4330	.	_	_	_	_

#Text=We hope this special issue provides a wealth of basic scientific data and introduces new concepts pertaining to ISGs that are regulated independently of IFN signaling .
26-1	4331-4333	We	person	giv	_	_
26-2	4334-4338	hope	_	_	_	_
26-3	4339-4343	this	abstract[245]	giv[245]	_	_
26-4	4344-4351	special	abstract[245]	giv[245]	_	_
26-5	4352-4357	issue	abstract[245]	giv[245]	_	_
26-6	4358-4366	provides	_	_	_	_
26-7	4367-4368	a	abstract[246]	new[246]	_	_
26-8	4369-4375	wealth	abstract[246]	new[246]	_	_
26-9	4376-4378	of	abstract[246]	new[246]	_	_
26-10	4379-4384	basic	abstract[246]|abstract[247]	new[246]|new[247]	_	_
26-11	4385-4395	scientific	abstract[246]|abstract[247]	new[246]|new[247]	_	_
26-12	4396-4400	data	abstract[246]|abstract[247]	new[246]|new[247]	_	_
26-13	4401-4404	and	_	_	_	_
26-14	4405-4415	introduces	_	_	_	_
26-15	4416-4419	new	abstract[248]	new[248]	_	_
26-16	4420-4428	concepts	abstract[248]	new[248]	_	_
26-17	4429-4439	pertaining	abstract[248]	new[248]	_	_
26-18	4440-4442	to	abstract[248]	new[248]	_	_
26-19	4443-4447	ISGs	abstract[248]|abstract[249]	new[248]|giv[249]	_	_
26-20	4448-4452	that	abstract[248]|abstract[249]	new[248]|giv[249]	_	_
26-21	4453-4456	are	abstract[248]|abstract[249]	new[248]|giv[249]	_	_
26-22	4457-4466	regulated	abstract[248]|abstract[249]	new[248]|giv[249]	_	_
26-23	4467-4480	independently	abstract[248]|abstract[249]	new[248]|giv[249]	_	_
26-24	4481-4483	of	abstract[248]|abstract[249]	new[248]|giv[249]	_	_
26-25	4484-4487	IFN	abstract[248]|abstract[249]|abstract|abstract[251]	new[248]|giv[249]|giv|giv[251]	_	_
26-26	4488-4497	signaling	abstract[248]|abstract[249]|abstract[251]	new[248]|giv[249]|giv[251]	_	_
26-27	4498-4499	.	_	_	_	_
